- Conditions
- Parkinson Disease
- Interventions
- Placebo, UCB0022
- Other · Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 61
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 53 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2737–2760
of 33,600
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Preeclampsia
- Interventions
- Recombinant human antithrombin (ATryn), Normal Saline 0.9%
- Biological · Other
- Lead sponsor
- rEVO Biologics
- Industry
- Eligibility
- 16 Years and older · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 19 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- AL001, Placebo
- Drug
- Lead sponsor
- Alector Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Boston, Massachusetts • St Louis, Missouri
- Conditions
- Hepatic Impairment
- Interventions
- Brensocatib
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Rialto, California • Orlando, Florida • San Antonio, Texas
- Conditions
- Dry Age-Related Macular Degeneration
- Interventions
- Avacincaptad Pegol
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HIV Infections
- Interventions
- Aldesleukin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Years to 12 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2001
- U.S. locations
- 14
- States / cities
- Long Beach, California • San Francisco, California • Aurora, Colorado + 8 more
- Conditions
- Idiopathic Thrombocytopenic Purpura
- Interventions
- Eltrombopag, Avatrombopag, Standard of care
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Watertown, South Dakota
- Conditions
- Rheumatoid Arthritis
- Interventions
- CP-690,550, Placebo, Biologic TNFi
- Drug · Other · Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 717 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 38
- States / cities
- Gilbert, Arizona • Glendale, Arizona • Mesa, Arizona + 33 more
- Conditions
- Gaucher Disease, Type 1
- Interventions
- FLT201
- Genetic
- Lead sponsor
- Spur Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Fairfax, Virginia
- Conditions
- Colonoscopy
- Interventions
- BLI-800, Polyethylene glycol 3350 based bowel preparation
- Drug
- Lead sponsor
- Braintree Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 10
- States / cities
- Anaheim, California • Orange, California • Jackson, Mississippi + 7 more
- Conditions
- Circadian Rhythm Sleep Disorders, Non-24 Hour Sleep-Wake Disorder, Autism Spectrum Disorder, Smith-Magenis Syndrome
- Interventions
- tasimelteon
- Drug
- Lead sponsor
- Vanda Pharmaceuticals
- Industry
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Actinic Keratosis
- Interventions
- Vehicle gel, SR-T100 with 2.3% of SM
- Drug
- Lead sponsor
- G&E Herbal Biotechnology Co., LTD
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 8
- States / cities
- Rancho Mirage, California • Longmont, Colorado • West Palm Beach, Florida + 4 more
- Conditions
- Crohn's Disease
- Interventions
- Adalimumab
- Biological
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 777 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 63
- States / cities
- Huntsville, Alabama • Jacksonville, Alabama • La Jolla, California + 56 more
- Conditions
- Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
- Interventions
- SPT-300, Placebo
- Drug
- Lead sponsor
- Seaport Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 29
- States / cities
- Chino, California • Garden Grove, California • Glendale, California + 25 more
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- K-877, Fenofibrate, Placebo (for K-877), Placebo (for Fenofibrate)
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 551 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 110
- States / cities
- Birmingham, Alabama • Hamilton, Alabama • Huntsville, Alabama + 94 more
- Conditions
- Schizophrenia
- Interventions
- RBP-7000, risperidone
- Drug
- Lead sponsor
- Indivior Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Willingboro, New Jersey
- Conditions
- Cytomegalovirus Infections
- Interventions
- Hepatitis A Vaccine, Towne CMV Vaccine
- Biological
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 82 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- HCV Infection
- Interventions
- VCH 916, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Dallas, Texas • San Antonio, Texas
- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- AGN-193408 SR, Lumigan, Sham Administration, Lumigan Vehicle
- Drug · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 42
- States / cities
- Sun City, Arizona • Glendale, California • Inglewood, California + 38 more
- Conditions
- Seizures
- Interventions
- Retigabine, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 539 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Dallas, Texas
- Conditions
- Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7, Stage IB Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
- Interventions
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis, Pharmacological Study, Stereotactic Body Radiation Therapy, Zoledronic Acid
- Drug · Other · Radiation
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma, Endometrial Adenocarcinoma, Ovarian Adenocarcinoma
- Interventions
- DBC-664
- Biological
- Lead sponsor
- Duboce Biopharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 7
- States / cities
- Denver, Colorado • Grand Rapids, Michigan • St Louis, Missouri + 4 more
- Conditions
- Meningitis, Meningococcal Infection
- Interventions
- Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined), M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live, Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Rotavirus Vaccine, Hepatitis B Vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 42 Days to 365 Days
- Enrollment
- 580 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Jonesboro, Arkansas + 20 more
- Conditions
- Acute Promyelocytic Leukemia
- Interventions
- Tamibarotene
- Drug
- Lead sponsor
- CytRx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Houston, Texas